Overview

RephImmune, is developing a novel cell therapy called RACE to provide late-stage cancer patients, who are running out of treatment options, with a low-dose, single-administration treatment that is more efficient, safer, and long-lasting. We compete in the growing cell therapy market, which last year was valued at $4.85 billion. Unlike convention CAR-T, our RACE offers a more potent and balanced immune response by bypassing conventional T cell signaling pathways. Currently, we have promising preclinical data demonstrating our RACE’s efficacy and safety in treating ovarian and breast cancer. Our team has extensive experience in cell and gene therapy, including key players from first CAR-T FDA approval. We are seeking investment and strategic partnerships. This funding will enable us to complete critical IND-enabling experiments, finalize our IND application, and secure in-human data from an investigator-initiated clinical trial. Your support will help us advance to clinical trials and make a meaningful impact on patient lives. Thank you for considering joining us on this transformative journey.